The report provides a detailed analysis essential for establishing a Linagliptin production plant. It encompasses all critical aspects necessary for Linagliptin production, including the cost of Linagliptin production, Linagliptin plant cost, Linagliptin production costs, and the overall Linagliptin production plant cost. Additionally, the study covers specific expenditures associated with setting up and operating a Linagliptin production plant. These encompass production processes, raw material requirements, utility requirements, infrastructure needs, machinery and technology requirements, manpower requirements, packaging requirements, transportation requirements, and more.
Linagliptin is an oral antihyperglycemic drug used to treat type-2 diabetes mellitus. It increases the level of a hormone called incretin. This mechanism of action increases the secretion of insulin and decreases the level of glucagon in the blood circulation. It is also used with other hypoglycemic drugs such as Metformin and Sulfonylureas, which increases its role in controlling the blood glucose levels in patients with type-2 diabetes mellitus. Thus, it finds its application in the pharmaceutical and medical industries.
The procurement of Linagliptin is influenced by its application in the pharmaceutical and medical industries to treat type-2 diabetes mellitus. It is used as an oral antihyperglycemic to increase the secretion of insulin and decrease the level of glucagon in patients. The global demand for Linagliptin has increased due to the increasing cases of type-2 diabetes mellitus. The aging population, along with poor diet and disturbed lifestyle, has also increased the demand for antidiabetic drugs such as Linagliptin. It is also used with other antidiabetic drugs such as Metformin and Sulfonylureas, which increases its role in controlling the blood glucose levels in patients, thus increasing its market growth.
It is available as an oral drug which makes it easy to intake and enhances patient compliance. Healthcare and technological advancements provide better accessibility for antidiabetic drugs such as Linagliptin, which further drives its market. It is known to show fewer side effects, which makes it safe to be used for longer periods. Overall, the industrial Linagliptin procurement is influenced by its applications in the pharmaceutical and medical industries, the increase in the cases of type-2 diabetes, the aging population, its use with other antidiabetic drugs, fewer side effects, healthcare and technological advancements, patient compliance, cost-effectiveness, research and development, logistics and distribution, and regulatory approvals.
Raw Material for Linagliptin Production
According to the Linagliptin production plant project report, the key raw material used in the production of Linagliptin include 1-(2-aminophenyl)ethenone.
Production Process of Linagliptin
The extensive Linagliptin production cost report consists of the following major industrial production process:
- Production from 1-(2-aminophenyl)ethenone: The production process of Linagliptin involves a cyclization reaction of 1-(2-aminophenyl)ethanone and 2-chloroacetonitrile in the presence of Hydrogen chloride to form an intermediate. The intermediate is then treated with 8-bromo-7-(but-2-yn-1-yl)-3-methyl-1H-purine-2,6(3H,7H)-dione in the presence of sodium carbonate to produce another intermediate. Furthermore, the intermediate undergoes a condensation reaction with (R)-2-(piperidin-3-yl)isoindoline-1,3-dione D-(−)-tartaric acid using diisopropylethylamine, to obtain a compound. Finally, this compound is subjected to aminolysis with ethanolamine to yield Linagliptin.
Linagliptin, commercially known as Tradjenta, is a white-to-yellow crystalline solid, having the molecular formula C25H28N8O2 and a molecular weight of 472.5 g/mol. Its melting point is 202 °C. Its water solubility is <1 mg/mL. Its pKa value is 9.86. It is soluble in soluble in methanol, sparingly soluble in ethanol, and slightly soluble is isopropanol. It is stable at normal conditions; however, it should be avoided from oxidizing agents. It is slightly hygroscopic. Linagliptin is an oral antihyperglycemic drug. It is a DPP-4 inhibitor used to treat type-2 diabetes mellitus by increasing the secretion of insulin and decreasing the levels of glucagon.
